
- /
- Supported exchanges
- / US
- / CRDL.NASDAQ
Cardiol Therapeutics Inc Class A (CRDL NASDAQ) stock market data APIs
Cardiol Therapeutics Inc Class A Financial Data Overview
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Cardiol Therapeutics Inc Class A data using free add-ons & libraries
Get Cardiol Therapeutics Inc Class A Fundamental Data
Cardiol Therapeutics Inc Class A Fundamental data includes:
- Net Revenue:
- EBITDA: -40 178 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-19
- EPS/Forecast: -0.0997
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cardiol Therapeutics Inc Class A News

Cardiol rises on database lockup for acute myocarditis therapy trial
[Stethoscope] adventtr/E+ via Getty Images * Cardiol Therapeutics (NASDAQ:CRDL [https://seekingalpha.com/symbol/CRDL]) shares up after it announced database lock for a mid-stage trial testing its l...


Cardiol Therapeutics announces database lock for myocarditis trial
TORONTO - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL), a clinical-stage biotechnology company with a current market capitalization of $100.83 million, announced Tuesday the database lock for it...

Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research ...

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT
Oakville, Ontario--(Newsfile Corp. - June 27, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.